101 related articles for article (PubMed ID: 12959297)
21. A bioavailability/bioequivalence study of two oral lansoprazole formulations after single administration to healthy volunteers.
Jovanović D; Kilibarda V; Maksimović M
Pharmazie; 2001 Oct; 56(10):800-2. PubMed ID: 11683127
[TBL] [Abstract][Full Text] [Related]
22. Pharmacokinetics of lansoprazole in patients with renal or liver disease of varying severity.
Delhotal-Landes B; Flouvat B; Duchier J; Molinie P; Dellatolas F; Lemaire M
Eur J Clin Pharmacol; 1993; 45(4):367-71. PubMed ID: 8299672
[TBL] [Abstract][Full Text] [Related]
23. The effect of aging on the relationship between the cytochrome P450 2C19 genotype and omeprazole pharmacokinetics.
Ishizawa Y; Yasui-Furukori N; Takahata T; Sasaki M; Tateishi T
Clin Pharmacokinet; 2005; 44(11):1179-89. PubMed ID: 16231968
[TBL] [Abstract][Full Text] [Related]
24. Comparative pharmacokinetics and pharmacodynamics of lansoprazole oral capsules and suspension in healthy subjects.
Doan TT; Wang Q; Griffin JS; Lukasik NL; O'Dea RF; Pan WJ
Am J Health Syst Pharm; 2001 Aug; 58(16):1512-9. PubMed ID: 11515348
[TBL] [Abstract][Full Text] [Related]
25. Identification of a single time-point for plasma lansoprazole measurement that adequately reflects area under the concentration-time curve.
Niioka T; Yasui-Furukori N; Uno T; Sugawara K; Kaneko S; Tateishi T
Ther Drug Monit; 2006 Jun; 28(3):321-5. PubMed ID: 16778714
[TBL] [Abstract][Full Text] [Related]
26. Formation of omeprazole sulphone but not 5-hydroxyomeprazole is inhibited by grapefruit juice.
Tassaneeyakul W; Vannaprasaht S; Yamazoe Y
Br J Clin Pharmacol; 2000 Feb; 49(2):139-44. PubMed ID: 10671908
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazole.
Andersson T; Holmberg J; Röhss K; Walan A
Br J Clin Pharmacol; 1998 Apr; 45(4):369-75. PubMed ID: 9578184
[TBL] [Abstract][Full Text] [Related]
28. Pharmacokinetic-pharmacodynamic study of oral lansoprazole in children.
Tran A; Rey E; Pons G; Pariente-Khayat A; D'Athis P; Sallerin V; Dupont C
Clin Pharmacol Ther; 2002 May; 71(5):359-67. PubMed ID: 12011821
[TBL] [Abstract][Full Text] [Related]
29. A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers.
Frelinger AL; Lee RD; Mulford DJ; Wu J; Nudurupati S; Nigam A; Brooks JK; Bhatt DL; Michelson AD
J Am Coll Cardiol; 2012 Apr; 59(14):1304-11. PubMed ID: 22464259
[TBL] [Abstract][Full Text] [Related]
30. Effect of four lansoprazole dose levels and one dosage regimen of omeprazole on 24-hour intragastric pH in healthy subjects.
Timmer W; Ripke H; Kleist P; Ehrlich A; Wieckhorst G; Lücker PW; Fuder H
Methods Find Exp Clin Pharmacol; 1995 Sep; 17(7):489-95. PubMed ID: 8577212
[TBL] [Abstract][Full Text] [Related]
31. Effects on 24-hour intragastric pH: a comparison of lansoprazole administered nasogastrically in apple juice and pantoprazole administered intravenously.
Freston J; Chiu YL; Pan WJ; Lukasik N; Täubel J
Am J Gastroenterol; 2001 Jul; 96(7):2058-65. PubMed ID: 11467632
[TBL] [Abstract][Full Text] [Related]
32. Dose-dependent inhibition of CYP3A activity by clarithromycin during Helicobacter pylori eradication therapy assessed by changes in plasma lansoprazole levels and partial cortisol clearance to 6beta-hydroxycortisol.
Ushiama H; Echizen H; Nachi S; Ohnishi A
Clin Pharmacol Ther; 2002 Jul; 72(1):33-43. PubMed ID: 12152002
[TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetic differences between lansoprazole enantiomers and contribution of cytochrome P450 isoforms to enantioselective metabolism of lansoprazole in dogs.
Masa K; Hamada A; Arimori K; Fujii J; Nakano M
Biol Pharm Bull; 2001 Mar; 24(3):274-7. PubMed ID: 11256484
[TBL] [Abstract][Full Text] [Related]
34. Effect on bioavailability of admixing the contents of lansoprazole capsules with selected soft foods.
Chun AH; Erdman K; Zhang Y; Achari R; Cavanaugh JH
Clin Ther; 2000 Feb; 22(2):231-6. PubMed ID: 10743982
[TBL] [Abstract][Full Text] [Related]
35. Effect of high-dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19.
Furuta T; Shirai N; Xiao F; Ohashi K; Ishizaki T
Clin Pharmacol Ther; 2001 Nov; 70(5):484-92. PubMed ID: 11719736
[TBL] [Abstract][Full Text] [Related]
36. Enantioselective disposition of omeprazole, pantoprazole, and lansoprazole in a same Brazilian subjects group.
Cassiano NM; Oliveira RV; Bernasconi GC; Cass QB
Chirality; 2012 Apr; 24(4):289-93. PubMed ID: 22344845
[TBL] [Abstract][Full Text] [Related]
37. Enantioselective disposition of lansoprazole in extensive and poor metabolizers of CYP2C19.
Kim KA; Shon JH; Park JY; Yoon YR; Kim MJ; Yun DH; Kim MK; Cha IJ; Hyun MH; Shin JG
Clin Pharmacol Ther; 2002 Jul; 72(1):90-9. PubMed ID: 12152007
[TBL] [Abstract][Full Text] [Related]
38. Lack of significant effect of grapefruit juice on the pharmacokinetics of lansoprazole and its metabolites in subjects with different CYP2C19 genotypes.
Uno T; Yasui-Furukori N; Takahata T; Sugawara K; Tateishi T
J Clin Pharmacol; 2005 Jun; 45(6):690-4. PubMed ID: 15901751
[No Abstract] [Full Text] [Related]
39. A novel option for dosing of proton pump inhibitors: dispersion of lansoprazole orally disintegrating tablet in water via oral syringe.
Gremse DA; Donnelly JR; Kukulka MJ; Lloyd E; Lee C
Aliment Pharmacol Ther; 2004 Jun; 19(11):1211-5. PubMed ID: 15153174
[TBL] [Abstract][Full Text] [Related]
40. Dose-response evaluation of the antisecretory effect of continuous infusion intravenous lansoprazole regimens over 48 h.
Howden CW; Metz DC; Hunt B; Vakily M; Kukulka M; Amer F; Samra N
Aliment Pharmacol Ther; 2006 Apr; 23(7):975-84. PubMed ID: 16573800
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
